Measuring changes in *Plasmodium falciparum* census population size in

response to sequential malaria control interventions

Kathryn E. Tiedje[1,2§], Qi Zhan[3,4§], Shazia Ruybal-Pésantez[2†], Gerry Tonkin-Hill[2,5], Qixin He[4‡], Mun Hua Tan[1], Dionne C. Argyropoulos[1], Samantha L. Deed[1,2], Anita Ghansah[6], Oscar Bangre[7], Abraham R. Oduro[7], Kwadwo A. Koram[8], Mercedes Pascual[9,10], and Karen P. Day[1,2]

[1] Department of Microbiology and Immunology, Bio21 Institute and Peter Doherty Institute for Infection and Immunity, The University of Melbourne; Melbourne, Australia
[2] School of BioSciences, Bio21 Institute, The University of Melbourne; Melbourne, Australia
[3] Committee on Genetics, Genomics and Systems Biology, The University of Chicago; Chicago, Illinois, USA
[4] Department of Ecology and Evolution, The University of Chicago; Chicago, Illinois, USA
[5] Bioinformatics Division, Walter and Eliza Hall Institute; Melbourne, Australia
[6] Department of Parasitology, Noguchi Memorial Institute for Medical Research, University of Ghana; Legon, Ghana
[7] Navrongo Health Research Centre, Ghana Health Service; Navrongo, Ghana
[8] Epidemiology Department, Noguchi Memorial Institute for Medical Research, University of Ghana; Legon, Ghana
[9] Department of Biology and Department of Environmental Sciences, New York University, New York, New York, USA
[10] Santa Fe Institute, Santa Fe, New Mexico, USA

† *Current affiliations:* Department of Infectious Disease Epidemiology and MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, United Kingdom

‡ *Current affiliation:* Department of Biological Sciences, Purdue University; West Lafayette, United States

§ These authors share first authorship

* Corresponding Author: Karen P. Day, Department of Microbiology and Immunology, Bio21 Institute and Peter Doherty Institute for Infection and Immunity, The University of Melbourne, 30 Flemington Road, Parkville, VIC, 3011, Australia. E-mail: Karen.Day@unimelb.edu.au, Phone: +613 8344 2377

RUNNING TITLE: Impact of IRS and SMC on census population size

ABSTRACT

Here we introduce a new endpoint "census population size" to evaluate the epidemiology and control of *Plasmodium falciparum* infections, where the parasite, rather than the infected human host, is the unit of measurement. To calculate census population size, we rely on a definition of parasite variation known as multiplicity of infection (MOI_{var}), based on the hyper-diversity of the *var* multigene family. We present a Bayesian approach to estimate MOI_{var} from sequencing and counting the number of unique DBLα tags (or DBLα types) of *var* genes, and derive from it census population size by summation of MOI_{var} in the human population. We track changes in this parasite population size and structure through sequential malaria interventions by indoor residual spraying (IRS) and seasonal malaria chemoprevention (SMC) from 2012 to 2017 in an area of high-seasonal malaria transmission in northern Ghana. Following IRS, which reduced transmission intensity by > 90% and decreased parasite prevalence by ~40-50%, significant reductions in *var* diversity, MOI_{var}, and population size were observed in ~2,000 humans across all ages. These changes, consistent with the loss of diverse parasite genomes, were short lived and 32-months after IRS was discontinued and SMC was introduced, *var* diversity and population size rebounded in all age groups except for the younger children (1-5 years) targeted by SMC. Despite major perturbations from IRS and SMC interventions, the parasite population remained very large and retained the *var* population genetic characteristics of a high-transmission system (high *var* diversity; low *var* repertoire similarity) demonstrating the resilience of *P. falciparum* to short-term interventions in high-burden countries of sub-Saharan Africa.

INTRODUCTION

Malaria in high-transmission endemic areas of sub-Saharan Africa (SSA) is characterised by vast diversity of the *Plasmodium falciparum* parasites from the perspective of antigenic variation (Chen et al., 2011; Day et al., 2017; Otto et al., 2019; Ruybal-Pesántez et al., 2022, 2017). As with other hosts of hyper-variable pathogens (Futse et al., 2008), children experiencing clinical episodes of malaria, eventually become immune to disease but not to infection. This results in a large reservoir of chronic asymptomatic infections, in hosts of all ages, sustaining transmission to mosquitos. Given the goal of malaria eradication by 2050, it is therefore of interest to examine how the parasite population changes following perturbation by major intervention efforts, both in terms of its size and underlying population genetics.

So, what do we mean by the parasite population size in the case of *P. falciparum* and how do we measure it? Parasite prevalence, detected by microscopy or more sensitive molecular diagnostics (e.g., PCR), describes the proportion of infected human hosts. Studies of *P. falciparum* genetic diversity have shown that the majority of people in high-transmission endemic areas harbour diverse multiclonal infections measured as the complexity or multiplicity of infection (MOI) (e.g., (Anderson et al., 2000; Paul et al., 1995; Smith et al., 1999; Sumner et al., 2021)) with complex population dynamics (Bruce et al., 2000; Farnert et al., 1997). These genetic data indicate much larger parasite population sizes than observed by prevalence of infection alone. Thus, from an ecological perspective, we can consider a human host as a patch carrying a number of "antigenically-distinct infections" of *P. falciparum*. The sum of these antigenically-distinct infections over all sampled hosts provides us with a census of the parasite count of relevance to monitoring and evaluating malaria interventions. We refer to this census population size hereafter simply as population size but make clear that this measure is distinct from effective population

size (N_e) as measured by neutral variation. This count can be scaled from the host sample to the larger

denominator of a host population in the area of interest.

Diversity of *P. falciparum* single copy surface antigen genes such as circumsporozoite protein (*csp*),

merozoite surface protein 1 (*msp1*) or 2 (*msp2*), and apical membrane antigen 1 (*ama1*) have each been

widely used to measure MOI (e.g., (Falk et al., 2006; Lerch et al., 2017; Nelson et al., 2019)). They have

become part of newer genetic panels (e.g., Paragon v1 (Tessema et al., 2020) and AMPLseq v1 (LaVerriere

et al., 2022)) specifically for MOI determination. Typically, MOI is reported as the maximum number of

alleles or single locus haplotypes present at the most diverse of these antigen-encoding loci rather than

the number of unique multilocus haplotypes of these genes combined, as it is challenging to accurately

reconstruct or phase these haplotypes in hosts with an MOI > 3 (Lerch et al., 2019). Each of these genes

is under balancing selection with a few geographically-common haplotypes and many very rare haplotypes

in moderate- to high-transmission settings (Markwalter et al., 2022; Sumner et al., 2021). Where there is

a high probability of co-occurrence of two or more common single locus haplotypes in a host, genotyping

each of these single copy antigen genes alone will underestimate MOI. Single nucleotide polymorphism

(SNP) panels have been used to define the presence of multiclonal infections with limited reliability to

estimate MOI for highly complex infections, typical in high transmission, even with the use of

computational methods (Labbé et al., 2023).

As an alternative to genotyping single copy antigen genes and biallelic SNP panels to estimate MOI, we

have proposed the use of a fingerprinting methodology known as *var*coding to genotype the hyper-diverse

var multigene family (~50-60 *var* genes per haploid genome). This method employs a ~450bp region of a

var gene, known as a DBLα tag encoding the immunogenic Duffy-binding-like alpha (DBLα) domain of

PfEMP1 (*Plasmodium falciparum* erythrocyte membrane protein 1), the major surface antigen of the

blood stages (Zhang and Deitsch, 2022). Bioinformatic analyses of a large database of exon 1 sequences

of *var* genes showed a predominantly 1-to-1 DBLα-*var* relationship, such that each DBLα tag typically

represents a unique *var* gene, especially in high transmission (Tan et al., 2023). The extensive diversity of

DBLα tags together with the very low percentage of *var* genes shared between parasites (Chen et al.,

2011; Day et al., 2017; Ruybal-Pesántez et al., 2022, 2017) facilitate measuring MOI by amplifying, pooling,

sequencing, and counting the number of unique DBLα tags (or DBLα types) in a host (Ruybal-Pesántez et

al., 2022; Tiedje et al., 2022). From a single PCR with degenerate primers and amplicon sequencing, the

method specifically counts the most diverse DBLα types, designated non-upsA, per infection to arrive at

a metric we call MOI_{var}. It is not based on assigning haplotypes but exploits the fact that *var* repertoires

are non-overlapping, especially in high transmission. Instead, it assumes a set number of non-upsA types

per genome based on repeated sampling of 3D7 control isolates accounting for PCR sampling errors to

calculate MOI_{var} (Ghansah et al., 2023; Ruybal-Pesántez et al., 2022; Tiedje et al., 2022). Consequently,

rather than looking at the diversity of a single copy antigen-encoding gene like *csp, msp2,* or *ama1* to

calculate MOI, by *var*coding we are looking at sets of up to 45 non-upsA DBLα types per genome. Prior

work has shown that *var*coding is more sensitive to measure MOI in high transmission where there is an

extremely high prevalence of multiclonal infections that cannot be accurately phased with either biallelic

SNP panels (Ghansah et al., 2023; Labbé et al., 2023; Tessema et al., 2020; Watson et al., 2021) or

combinations of single copy antigen genes (Sumner et al., 2021).

Here we report an investigation of changes in parasite census population size and structure through two sequential malaria control interventions between 2012 and 2017 in Bongo District located in the Upper East Region of Ghana, one of the 12 highest burden countries in Africa (World Health Organization, 2022). We present a novel Bayesian modification to the published *var*coding approach (Ghansah et al., 2023; Ruybal-Pesántez et al., 2022; Tiedje et al., 2022) that takes into account under-sampling of non-upsA DBLα types in an isolate to estimate MOI_{var} (Ruybal-Pesántez et al., 2022; Tiedje et al., 2022) and therefore population size. We document *P. falciparum* prevalence as well as *var* diversity and population structure from baseline in 2012 through a major perturbation by a short-term indoor residual spraying (IRS) campaign managed under operational conditions, which reduced transmission intensity by > 90% as measured by the entomological inoculation rate (EIR) and decreased parasite prevalence by ~40-50% (Tiedje et al., 2022). Next, we followed what happened to parasite population size more than two years after the IRS intervention was discontinued and seasonal malaria chemoprevention (SMC) was introduced for children between the ages of 3-59 months (i.e., < 5 years) (Wagman et al., 2018). Detectable changes in parasite population size were seen as a consequence of the IRS intervention but this quantity rapidly rebounded 32-months after the intervention ceased. Overall, throughout the IRS, SMC, and subsequent rebound, the parasite population in humans remained large in size and retained the *var* population genetic characteristics of high transmission (i.e., high *var* diversity, low *var* repertoire overlap), demonstrating the overall resilience of the species to survive significant short-term perturbations.

MATERIALS AND METHODS

Human subject ethical approval

The study was reviewed/approved by the ethics committees at the Navrongo Health Research Centre (Ghana), Noguchi Memorial Institute for Medical Research (Ghana), The University of Melbourne (Australia), The University of Chicago (United States), and New York University (United States). Details on the study area, study population, inclusion/exclusion criteria, and data collection procedures have been previously described (Tiedje et al., 2022, 2017).

Study design and sample collection

Using an interrupted time-series study design, four age-stratified cross-sectional surveys of ~2,000 participants per survey were undertaken to investigate the impacts of IRS and SMC in combination with long-lasting insecticidal nets (LLINs) impregnated with pyrethroids under operational conditions on the asymptomatic *P. falciparum* reservoir from two proximal catchment areas (i.e., Vea/Gowrie and Soe, with a sampling area of ~60 km^2) in Bongo District, Ghana (hereinafter referred to collectively as "Bongo"; (Tiedje et al., 2022, 2017)) (Table supplement 1). Bongo District, located in the Upper East Region, is categorized as high-seasonal malaria transmission based on the World Health Organization's (WHO) "A Framework for Malaria Elimination" (WHO/GMP, 2017) where *P. falciparum* prevalence was ≥ 35% at baseline in 2012 (Tiedje et al., 2022, 2017). These ~2,000 participants of all ages (1-97 years) represent ~15% of the total population that reside in these two catchment areas in Bongo (Tiedje et al., 2017). The four cross-sectional surveys were completed at the end of the wet season (i.e., high-transmission season) and the study can be separated into four distinct study time points: (1) October 2012 (Survey 1) prior to the IRS and SMC (i.e., baseline), (2) October 2014 (Survey 2) two months after the second round of IRS

(Actellic 50EC), (3) October 2015 (Survey 3) seven months after the third round of IRS using a long-acting

non-pyrethroid insecticide (Actellic 300CS) (Gogue et al., 2020; US President's Malaria Initiative Africa IRS

(AIRS) Project, 2016), and finally (4) October 2017 (Survey 4) 32-months after the discontinuation of IRS,

but during the deployment of SMC to all children 3-59 months (i.e., < 5 years) (Figure 1). LLINs (i.e.,

PermaNet 2.0, Olyset, or DawaPlus 2.0) were mass distributed in Bongo District by the National Malaria

Elimination Programme (NMEP)/Ghana Health Service (GHS) between 2010-2012 and again in 2016

following the discontinuation of IRS (Gogue et al., 2020; Tiedje et al., 2022; US Agency for International

Development (USAID) Global Health Supply Chain Program, 2020). In addition, to maintain high coverage

of LLINs between these campaigns continuous distribution was undertaken using routine services (i.e.,

antenatal clinics, school distributions, immunization visits, etc.) (Tiedje et al., 2022). Over the course of

this study self-reported LLIN usage the previous night remained high across all age groups, from 89.1% in

2012 (pre-IRS), 83.5% in 2014 (during IRS), 90.6% in 2015 (post-IRS), to 96.8% in 2017 (SMC). Details on

the study area, study population, and data collection procedures have been previously described (Tiedje

et al., 2022, 2017).

Details of the IRS and SMC interventions

Starting in 2013, the AngloGold Ashanti Malaria Control Programme (AGAMal) in a public-private

partnership with the Global Fund, scaled up IRS across all of the Upper East Region of northern Ghana

(Gogue et al., 2020). As part of this initiative, three rounds of IRS with organophosphate formulations (i.e.,

non-pyrethroid) were rolled out prior to the start of the wet season between 2013 and 2015 (Figure 1A)

in Bongo District (Tiedje et al., 2022). Based on AGAMal's operational reports, IRS coverage in Bongo

District was 91.8% in Round 1, 95.6% in Round 2, and finally 96.6% in Round 3 (AGAMal, personal

communication). To monitor the impact of the IRS on the local vector population, monthly entomological

collections were undertaken between February 2013 and September 2015 (Tiedje et al., 2022). Using

these surveys, we observed that the monthly entomological inoculation rate (EIR) (infective

bites/person/month (ib/p/m)), a measure of local transmission intensity, declined by > 90% at the peak of

the wet season between August 2013 (pre-IRS) (EIR = 5.3 ib/p/m) and August 2015 (post-IRS) (EIR = 0.4

ib/p/m) (Tiedje et al., 2022). Following the IRS, SMC was rolled out in the Upper East Region by the

NMEP/GHS starting in 2016 (Gogue et al., 2020) (Figure 1A). SMC is the intermittent administration of a

curative dose of an antimalarial to children between the ages of 3-59 months (i.e., < 5 years) (WHO, 2012).

Like other countries, the SMC drug combination of choice in Ghana is sulfadoxine-pyrimethamine plus

amodiaquine, which is administered at monthly intervals (i.e., ~28-30 days apart) during the high-

transmission season (i.e., wet season) (WHO, 2012). The goal of this age-targeted intervention is to both

clear current infections and prevent malarial illness by maintaining a therapeutic concentration of an

antimalarial in the blood over the period of greatest risk (i.e., high-transmission season). Reported SMC

coverage in Bongo District was 92.6% in 2016 (two cycles between August – September 2016) and 94.6%

in 2017 (four cycles between July – October 2017) (Gogue et al., 2020) (NMEP/GHS, personal

communication).

Var genotyping and sequence analysis

Genomic DNA was extracted from the dried blood spots for all participants with a confirmed microscopic

asymptomatic *P. falciparum* infection (i.e., isolate) (2,572 isolates, Table supplement 2) using the QIAamp

DNA mini kit (QIAGEN, USA) as previously described (Tiedje et al., 2017). For *var* genotyping or *var*coding,

the sequence region within the *var* genes encoding the DBLα domains of PfEMP1 were amplified using a

single-step PCR, pooled, and sequenced on an Illumina platform using the MiSeq Reagent Kit v3 (600 cycle;

2×300bp paired-end) (Supplemental Methods, Figure supplement 1). The raw sequence data was then

processed using our previously published customized bioinformatic pipelines (Supplemental Methods,

Figure supplement 2). For additional information on the use of these bioinformatic pipelines a detailed

tutorial is available (https://github.com/UniMelb-Day-Lab/tutorialDBLalpha).

DBLα sequencing data was obtained from 2,397 *P. falciparum* isolates (93.2%) (Table supplement 2). This

genotyping success was acceptable given that we were working with low-density asymptomatic infections

(Table supplement 1). Using a cut-off of ≥ 20 DBLα types, DBLα sequencing data was obtained from 2,099

P. falciparum isolates (81.6%) with a total of 289,049 DBLα sequences and 53,238 unique DBLα types

being identified in the study population (Table supplement 2). The median *P. falciparum* density was ~4

times higher for isolates with ≥ 20 DBLα types compared to those that gave no or < 20 DBLα types (520

[IQR: 200-1880] parasites/μL vs. 120 [IQR: 40-200] parasites/μL, respectively).

DBLα type diversity

We monitored the impacts of the sequential interventions (i.e., IRS and SMC) on diversity by measuring

changes in the population genetics of DBLα types at the population level (i.e., *P. falciparum* reservoir).

Diversity was monitored using two measures, DBLα type richness and DBLα type frequency. Richness was

defined as the number of unique DBLα types observed (i.e., DBLα type pool size) in each survey or study

time point (i.e., 2012, 2014, 2015, and 2017). DBLα type richness, however, does not provide any

information about the relative frequencies of the different DBLα types in the population, as they are all

weighted equally whether they are observed once or more frequently (e.g., observed in > 20 isolates per

survey). To further examine the impacts of the interventions on DBLα type diversity we also assessed the

frequency of each unique DBLα type in 2012, 2014, 2015, and 2017. Here we defined DBLα type frequency

as the number of times (i.e., number of isolates) a DBLα type was observed in each survey. Both upsA and

non-upsA DBLα type diversities were measured due to their different biological features, chromosomal

positions (i.e., subtelomeric regions vs. internal or central regions), as well as population genetics (Falk et

al., 2009; Gardner et al., 2002; Jensen et al., 2004; Kaestli et al., 2006; Kalmbach et al., 2010; Kraemer et

al., 2007; Kraemer and Smith, 2006; Kyriacou et al., 2006; Lavstsen et al., 2003; Normark et al., 2007;

Rottmann et al., 2006; Warimwe et al., 2012, 2009; Zhang and Deitsch, 2022). The proportions of upsA

and non-upsA *var* genes in a repertoire or single genome have been defined as ~15-20% and ~80-85%,

respectively, based on whole genome sequencing (Rask et al., 2010). The upsA and non-upsA DBLα type

proportions were partitioned as expected in our analyses, with the median proportions at the repertoire

level being comparable in 2012 (19% upsA and 81% non-upsA), 2014 (22% upsA and 78% non-upsA), 2015

(21% upsA and 79% non-upsA), and 2017 (20% upsA and 80% non-upsA).

Repertoire similarity as defined by pairwise type sharing

To estimate genetic similarity between the DBLα repertoires (i.e., unique DBLα types identified in each

isolate) identified from two isolates, pairwise type sharing (PTS) was calculated between all pairs of

isolates in each survey as previously described (Barry et al., 2007). PTS, analogous to the Sørensen Index,

is a similarity statistic to evaluate the proportion of DBLα types shared between two isolate repertoires

(i.e., DBLα repertoire overlap) and ranges from 0 (i.e., no DBLα repertoire overlap) to 1 (i.e., identical DBLα

isolate repertoires), where < 0.50 = unrelated, 0.5 = recent recombinants/siblings, > 0.5 = related, and 1

= clones. PTS is a measure of identity-by-state (IBS) used to assess repertoire similarity between isolates

and is not used to infer inheritance from a recent common ancestor (i.e., identity-by-decent (IBD)) (Speed

and Balding, 2015).

DBLα isolate repertoire size

For this study we have exploited the unique population structure of non-overlapping DBLα isolate

repertoires to estimate isolate MOI_{var}. To calculate MOI_{var}, the non-upsA DBLα types were chosen since

not only are they more diverse and less conserved between isolate repertoires (i.e., low median PTS_{non-}

$_{upsA}$ ≤ 0.020) compared to the upsA DBLα types, but they have also been shown to have a more specific 1-

to-1 relationship with a single *var* gene than upsA (Tan et al., 2023). The low to non-existent overlap of

repertoires enables an estimation of MOI that relies on the number of non-upsA DBLα types sequenced

from an individual's isolate (Ruybal-Pesántez et al., 2022; Tiedje et al., 2022). A constant repertoire size

or number of DBLα types in a parasite genome can be used to convert the number of types sequenced in

an isolate to estimate MOI (Ruybal-Pesántez et al., 2022; Tiedje et al., 2022). This approach, however,

neglects the measurement error in this size introduced by targeted PCR and amplicon sequencing of *var*

genes in an isolate.

Bayesian estimation of MOI_{var} and associated census population size

Here, we extend the method to a Bayesian formulation and estimate the posterior distribution for each

sampled individual for the probability of different MOI values. From individual posterior distributions, we

can then obtain the estimated MOI frequency distribution for the population as a whole. The two pieces

of information required for our approach are the measurement error and the prior distribution of MOI.

The measurement error is simply the repertoire size distribution, that is, the distribution of the number

of non-upsA DBLα types sequenced given MOI = 1, which is empirically available (Figure supplement 3

(Labbé et al., 2023)). We refer to it as P(s | MOI = 1) where *s* here denotes repertoire size. More generally

when MOI ≥ 1, *s* denotes the number of non-upsA DBLα types sequenced or isolate size. The prior

distribution of MOI refers to the belief we have for what the actual MOI distribution might look like at the

population level before empirical evidence is taken into consideration. For example, the prior distribution

of MOI is likely to centre around a higher value in high-transmission endemic areas than in low-

transmission ones.

We can obtain P(s | MOI = m) from the serial convolution of the repertoire size distribution P(s | MOI =

1) and P(s | MOI = m - 1). Starting with the repertoire size distribution given a single infection, we can

derive P(s | MOI = m) for *m* equal to 2,3,..., up until a maximum value of 20 (empirically determined), as

follows:

$$P(s \,|\, MOI = m) = \sum_{x=L}^{U} P(x \,|\, MOI = 1) \times P(s - x \,|\, MOI = m - 1)$$

284 1.1

285 where *L* and *U* are the lower and upper limit for the repertoire size, 10 and 45 respectively from the

286 empirical repertoire size distribution (Figure supplement 3 (Labbé et al., 2023)).

288 For simplicity, we begin with a uniform prior. We use Bayes' rule to derive a posterior distribution of

289 MOI given a certain number of non-upsA DBLα types sequenced from an individual:

$$P(MOI = j \,|\, s) = \frac{P(s \,|\, MOI = j) \times P(MOI = j)}{\sum_{i=1}^{k} P(s \,|\, MOI = i) \times P(MOI = i)}$$

1.2

where k is the maximum value of MOI, here 20, as empirically determined.

To obtain the MOI distribution at the population level, we could either simply pool the maximum *a*

posteriori MOI estimate for each sampled individual, or use a technique called mixture distribution. For

the latter, we weighed each posterior MOI distribution for each sampled individual equally and sum over

all posterior distributions at the individual level to derive the MOI distribution at the population level:

$$f(MOI = m) = \sum_{i=1}^{n} \frac{1}{n} P(MOI = m \,|\, s_i)$$
                     1.3

where n is the number of sampled individuals. These two approaches gave similar results for our empirical

survey data as determined by the Kolmogorov-Smirnov Test. The obtained distance statistic is close to 0

and the corresponding *p-value* is non-significant across all surveys, indicating that the two estimates were

drawn from the same distribution (Table supplements 3 and 4). Additionally, the difference between the

mean MOI values at the population level obtained from the two approaches is small (Table supplements

3 and 4). Given this similarity, we present the results based on pooling the maximum *a posteriori* MOI

estimates for each sampled individual in the main text and include the results based on mixture

distribution in the Supplemental Information. Note that we focused on individuals who had confirmed

microscopic asymptomatic P. *falciparum* infections for our MOI estimation.

To examine alternative priors, we considered empirical MOI distributions described in the literature

including the Poisson, hyper-Poisson, and negative binomial distributions (Dietz, 1988; Henry, 2020). The

hyper-Poisson and negative binomial distributions can capture the overdispersion seen in the empirical

distribution of MOI for certain areas and caused by factors such as heterogeneous biting. We therefore

focused on a negative binomial distribution and investigated changing its parameters to generate priors

with different means spanning a wide range of MOI values (mean MOI within [~1.5, ~6.7]), including those

seen in high-transmission endemic areas. A uniform prior and a zero-truncated negative binomial

distribution with parameters within the range typical of high-transmission endemic regions (higher mean

MOI, for example, ~4.3 versus ~6.7, with tails for higher MOI values in the range of 10-20) produce similar

MOI estimates at the population level (Table supplements 5 and 6). However, when setting the parameter

range of the zero-truncated negative binomial to be representative of those in low-transmission endemic

regions where the empirical MOI distribution centres around monoclonal infections with the majority of

MOIs = 1 or 2 (mean MOI $\approx$ 1.5, no tail at higher MOI values), the final population-level MOI distribution

does deviate more from that based on the aforementioned prior and parameter choices (Table

supplement 6). The final individual- and population-level MOI estimates are not sensitive to the specifics

of the prior MOI distribution as long as this distribution captures the tail for higher MOI values with above-

zero probability. The obtained Kolmogorov-Smirnov Test distance statistics and their corresponding *p-*

values, the Pearson correlation tests and their corresponding *p-values*, as well as the difference in mean

MOI values, for the comparison of the MOI estimates obtained with the different priors are included in

Table supplements 5 and 6. Given these comparisons, we provide in our analyses the estimated

population MOI distribution using a uniform prior.

Adjusting for differences in sampling depth across age groups and surveys in the census population

size calculation

In our interrupted time-series study design, we sampled the Bongo population by age group to assess age-

specific effects of the sequential interventions (i.e., IRS and SMC). Sampling depth by age group was

consistent across the four cross-sectional surveys (Table supplement 1), except for 1-5-years-olds in 2014.

To account for variation in sampling depth across age groups and surveys, we performed subsampling at

the level of the minimum number of individuals in each age group across all surveys. We calculated the

total number of *var* repertoires from a subsample of this number of individuals within each age group for

each survey. This approach ensures consistent sample sizes within each age group across all surveys. We

summed the *var* repertoires across age groups to obtain the total *var* repertoire count for each survey.

To calculate the mean and 95% CIs for the number of *var* repertoires (i.e., census population size), we

repeated the subsampling procedure 10,000 times and derived these quantities from the distribution of

these repeated subsampling replicates.

Statistical analysis

We used the R v4.3.1 for all data analyses with the collection of R packages in *tidyverse* being used for

data curation along with *base*, *stats, gtsummary,* and *epiR* for the statistical analyses (R Core Team, 2018;

Sjoberg, D et al., 2021; Stevenson, 2020; Wickham et al., 2019). Continuous variables are presented as

medians with interquartile ranges (IQRs) and discrete variables are presented using the observed or

calculated values with the 95% confidence interval (95% CIs) or ± 2 standard deviations (± 2SD). Kaplan-

Meier survival curves were generated for the time (i.e., number of surveys) to first event (i.e., when the

DBLα type was no longer observed/detected) comparing the upsA and non-upsA DBLα types; *p-values*

were determined using the log-rank test using the R packages *survival* and *survminer* (Kassambara et al.,

2021; Therneau, 2023). The time interval to first event considered for all survival curves was the number

of surveys or year (i.e., 2012, 2014, 2015, and 2017) that each DBLα type was observed and only includes

those upsA (N = 2,218) and non-upsA (N = 33,159) DBLα types that were seen at baseline in 2012 (i.e.,

those DBLα types observed prior to the IRS intervention) (Table supplement 2).

RESULTS

Between 2013 and 2015, three-rounds of IRS with non-pyrethroid insecticides were implemented across all of Bongo District. Coincident with the > 90% decrease in transmission following IRS (Tiedje et al., 2022), the prevalence of microscopic *P. falciparum* infections compared to the 2012 baseline survey (pre-IRS) declined by 45.2% and 35.7% following the second (2012 to 2014) and the third (2012 to 2015) round of IRS, respectively (Figure 1B, Table supplement 1). These declines in parasite prevalence were observed across all ages, with the greatest impacts being observed on the younger children (1-5 years) who were ~3 times less likely to have an infection in 2015 (post-IRS) compared to 2012 (pre-IRS) (Figure 1C, Table supplement 1). These reductions were however short-lived and in 2017, 32-months after the discontinuation of IRS, but during SMC, overall *P. falciparum* prevalence rebounded to 41.2%, or near pre-IRS levels (Figure 1B, Table supplement 1). Importantly, this increase in the prevalence of infection in 2017 was only observed among the older age groups (i.e., $\geq$ 6 years) (Figure 1C, Table supplement 1). This difference by age group in 2017 can be attributed to SMC, which only targets children between 3-59 months (i.e., < 5 years). A notable increase in parasite prevalence for adolescents (11-20 years) and adults (> 20 years) was found in 2017 relative to the 2012 (pre-IRS) (Figure 1C, Table supplement 1).

Next, we wanted to explore changes in population size measured by MOI_{var}. As this metric is based on non-overlap of *var* repertoire diversity of individual isolates, specifically non-upsA DBLα types, we investigated whether DBLα isolate repertoire similarity (or overlap), as measured by PTS, increased following the sequential interventions (i.e., IRS and SMC). Figure 2 shows that median PTS values for both upsA and non-upsA DBLα types remained low in all surveys, although the PTS distributions for both groups changed significantly at each of the study time points relative to the 2012 baseline survey (pre-IRS) (*p*-

values < 0.001, Kruskal-Wallis test) (Figure 2). Somewhat unexpectedly, the change was in the direction

of reduced similarity (i.e., less overlap) with lower median PTS scores and a larger number of isolates

sharing no DBLα types (i.e., PTS = 0) in 2014, 2015, and 2017 compared to 2012. Relevant to measurement

of MOI_{var}, the median PTS scores for non-upsA DBLα types were lower following the IRS intervention

($PTS_{non\text{-}upsA}$: 2014 = 0.013 and 2015 = 0.013 vs. $PTS_{non\text{-}upsA}$: 2012 = 0.020). In 2017, the non-upsA PTS

distributions shifted back towards higher median PTS scores ($PTS_{non\text{-}upsA}$ = 0.016) and fewer isolates shared

no DBLα types relative to 2014 and 2015 (Figure 2). To verify this pattern was not influenced by multiclonal

infections (MOI_{var} > 1) we also examined isolates with monoclonal infections (MOI_{var} = 1) and found that

this non-overlapping structure persisted regardless of infection complexity, particularly for the non-upsA

DBLα types (Figure supplement 4). These PTS data make clear that we were dealing with a large, highly

diverse parasite population where 99.9% of the isolate comparisons in all surveys had $PTS_{non\text{-}upsA}$ scores ≤

0.1 (i.e., shared ≤ 10% of their non-upsA DBLα types), indicating that DBLα isolate repertoires were highly

unrelated (Figure 2). In fact, throughout the IRS, SMC, and subsequent rebound, very few DBLα isolate

repertoires were observed to be related, with < 0.003% isolate comparisons in each survey having a $PTS_{non\text{-}}$

$_{upsA}$ ≥ 0.5 (i.e., siblings or recent recombinants) (Figure 2).

The raw data of non-upsA DBLα isolate repertoire sizes (Figure supplement 5) were used to estimate

MOI_{var} as adjusted using the Bayesian approach based on pooling the maximum *a posteriori* MOI estimates

(Figure 3) and the mixture distribution (Figure supplement 6). We observed that at baseline in 2012, the

majority (89.2%) of the population across all ages carried multiclonal infections (median MOI_{var} = 4 [IQR:

2 − 6]) (Figure 3A). Following the IRS intervention, the estimated MOI_{var} distributions became more

positively skewed, indicating that a lower proportion of participants harboured multiclonal infections with

a lower median MOI$_{var}$ in 2014 (64.5%; median MOI$_{var}$ = 2 [IQR: 1 − 3]) and 2015 (71.4%; median MOI$_{var}$ =

2 [IQR: 1 − 3]) compared to 2012 (Figure 3A). These reductions in median MOI$_{var}$ and the proportion of

multiclonal infections, which were observed across all age groups (Figure 3B), are consistent with the >

90% decrease in transmission intensity following the IRS in turn reducing exposure to new parasite

genomes. However, in 2017, both median MOI$_{var}$ (3 [IQR: 2 − 4]) and the proportion of multiclonal

infections (78.9%) rebounded in all age groups, even among the younger children (1-5 years)

predominantly targeted by SMC (Figure 3). While the prevalence of infection in 2017 remained low for

the younger children (1-5 years), those infected still carried multiclonal infections (84.1% of those

infected) (Figure 3B). Although the MOI$_{var}$ distributions across all age groups started to rebound in 2017

(i.e., less positively skewed compared to 2014 and 2015) they had not fully recovered to the 2012 baseline

patterns (Figure 3). This was most apparent among the younger children (1-5 years), as a larger proportion

of isolates in 2017, compared to 2012, had MOI$_{var}$ values equal to one or two, while a smaller proportion

had MOI$_{var}$ values ≥ 5 (Figure 3B).

Census population size, measured as the number of *P. falciparum var* repertoires circulating in the

population during each survey, was estimated by summation of isolate MOI$_{var}$ (see Materials and

Methods; Figure 4, Table supplement 7). In 2014 during IRS, this number decreased by 71.4% relative to

the 2012 baseline survey (pre-IRS) (Figure 4CE), whereas prevalence decreased by 54.5% (Figure 4CE).

Although census population size increased slightly in 2015 relative to 2014 (Figure 4A), there were still

64.4% fewer *var* repertoires in the population compared to 2012 (Figure 4CE) in comparison to a 42.6%

decrease in prevalence (Figure 4CE). Importantly this loss of *var* repertoires in 2014 and 2015 following

the IRS intervention was seen for all age groups (Figure 4B), with the greatest overall reductions (≥ 83.8%)

being observed for the younger children (1-5 years) (Figure 4DF). However, in 2017, the number of diverse

var repertoires in the population rebounded, more than doubling between 2015 and 2017 (Figure 4CE).

This increase in the number of *var* repertoires was seen for all age groups in 2017, except for the younger

children (1-5 years) where those up to 59 months were targeted by SMC (Figure 4BD). In fact, the greatest

overall increase was observed for the adolescents (11-20 years) and adults (> 20 years), where the number

of *var* repertoires in 2017 was ~1.2 times higher compared to 2012 (Figure 4F). Similar trends in the

number *var* repertoires were also observed for the older children (6-10 years) in 2017, although the

rebound was not as striking as that detected for the adolescents and adults.

As census population size changed considerably during the sequential IRS and SMC interventions, we

investigated how the removal or loss of *P. falciparum var* repertoires and subsequent rebound in 2017

altered DBLα type richness, measured as the number of unique upsA and non-upsA DBLα types in the

parasite population in each survey. Richness at baseline in 2012 (pre-IRS) was high with a large number of

unique DBLα types (upsA = 2,218; non-upsA = 33,159) (Figure 5, Table supplement 2) and limited overlap

of *var* repertoires (i.e., median $PTS_{non\text{-}upsA} \leq 0.020$) seen in a relatively small study population of 685

microscopically positive individuals (Figure 2). In 2014, as *P. falciparum* prevalence and census population

size declined (Figure 4) so too did the number of DBLα types, resulting in a 32.2% and 55.3% reduction in

richness for the upsA and non-upsA DBLα types, respectively, compared to 2012 (Figure 5, Table

supplement 2). Again in 2015, as *P. falciparum* prevalence and population size remained low (Figure 4)

DBLα type richness was still less than that observed in 2012 (24.6% and 46.0% reduction for upsA and

non-upsA DBLα types, respectively) (Figure 5, Table supplement 2). Finally, in 2017, we found that upsA

and non-upsA DBLα type richness rebounded relative to 2014 and 2015, coincident with the increase in

P. falciparum prevalence and census population size (Figure 4, Figure 5).

Given this reduction in DBLα type richness following the IRS intervention and subsequent rebound in 2017,

we wanted to explore whether the loss of richness was influenced by the frequency of individual DBLα

types in the parasite population within and among surveys. To answer this, we defined the relative

frequency of individual DBLα types in all isolates in each survey (Figure 6, Figure supplement 7). We

discovered that individual upsA and non-upsA DBLα types were not all at equal frequencies within a survey

and among surveys. They could be classified as frequent (i.e., observed in 11-20 or > 20 isolates), less

frequent (i.e., observed in 2-10 isolates) or only seen once, at baseline in 2012 (Figure 6AB). In 2014 and

2015, following IRS, there was a significant increase in the proportion of upsA and non-upsA DBLα types

in the lower frequency categories (*p-value* < 0.001, Mann-Whitney U test), with all DBLα types becoming

rarer in the population (Figure 6CD). This change can be attributed to the removal of *P. falciparum var*

repertoires (Figure 4) with associated loss of upsA and non-upsA DBLα type richness (Figure 5), which

disproportionally affected those DBLα types seen once. This shift to all DBLα types becoming rarer

following IRS changed in 2017, where the proportion of DBLα types in the more frequent categories (i.e.,

2-10, 11-20, or > 20 isolates) significantly increased while the proportion seen once decreased (*p-values*

< 0.001, Mann-Whitney U tests) (Figure 6CD). Data in Figure 6 (A-D) pointed to a differential effect of the

IRS intervention and subsequent rebound on the less frequent upsA and non-upsA DBLα types vs. those

that were classified as frequent, where those DBLα types that were most frequent persisted longitudinally.

To explore this observation further we restricted the longitudinal analysis to those DBLα types from the

baseline survey in 2012 (pre-IRS). We compared the probability of survival for the DBLα types identified

at baseline in 2012 and found that the upsA DBLα types persisted significantly longer in the population

relative to the non-upsA DBLα types ($p < 0.001$, log-rank test), despite the IRS intervention. The simple

explanation being that although the upsA DBLα types had lower richness (Figure 5), a larger proportion

was classified as frequent indicating that multiple copies existed in the population compared to the non-

upsA DBLα types (Figure 6CD). Furthermore, when we examined survival using the frequency categories,

the upsA and non-upsA DBLα types that were observed at multiple study time points (i.e., 2012, 2014,

2015, and 2017), albeit in different isolate repertoires, were those that were most frequent (i.e., observed

in 11-20 and >20 isolates) in the population at baseline in 2012 (Figure 6EF). As expected, the DBLα types

that were only observed once in 2012, were significantly less likely to be seen longitudinally (*p-value* <

0.001, log-rank test) (Figure 6EF). These differential changes in DBLα type richness with respect to rare vs.

frequent DBLα types are a consequence of changes in census population size with interventions (Figure

4) where each isolate repertoire is composed of many rare DBLα types as defined by PTS (Figure 2).

DISCUSSION

P. falciparum populations in high-transmission endemic areas in SSA, are characterised by extensive diversity, high rates of recombination, as well as frequent multiclonal infections. Here we defined census population size of *P. falciparum* to understand total parasite diversity in a human population and explore the age-specific efficacy of malaria interventions to reduce this metric in such areas as typified by Bongo, Ghana. Census population size proved more informative than parasite prevalence alone because it captures "within" host parasite population size as MOI, rather than using the infected host per se as a unit of population size. Whilst the concept of census population size is agnostic of how you measure MOI, the extensive DBLα isolate repertoire diversity presented makes a strong case for fingerprinting parasite isolates by *var*coding in high transmission. This is opposed to looking at allelic diversity of a single copy antigen gene, such as *csp*.

Census population size is a total enumeration or count of infections in a given population sample and over a given time period in an ecological sense, distinct from the formal effective population size (N_e) used in population genetics (Charlesworth, 2009). Given the low overlap between *var* repertoires of parasites observed in monoclonal infections (MOI = 1), the census population size calculated in Bongo, Ghana translates to a diversity of strains or repertoires. The distinction of census population size in terms of infection counts and effective population size from population genetics has been made before for pathogens, including the seasonal influenza virus and the measles virus (Bedford et al., 2011); it is also a distinction made in the ecological literature for non-pathogen populations (Palstra and Fraser, 2012). The census population size of a given population sample depends of course on sample size and was used here for comparisons across time of samples of the same depth (i.e., ~2,000 individuals). There is, however, a

simple map between census population size and mean MOI, as one can simply divide or multiply by the

sample size, respectively, to convert between the two quantities (Table supplement 7). Therefore, one

can extrapolate from the census population size of a given population sample to that of the whole

population of local hosts in a given area to compare across studies that differ in sampling depth and/or

spatial extent. What is needed for this extrapolation is a stable mean MOI relative to the sample size or

sampling depth, which is indeed the case in this study (Figure supplement 8) and can be easily checked in

other studies. Given the typical duration of infection, we expect our population size to be representative

of a per-generation measure.

By *var*coding we identified a very large census parasite population size in a relatively small human

population of ~2,000 individuals at baseline and captured age-specific changes in this metric in response

to sequential malaria control interventions. IRS reduced the MOI_{var} parasite population size substantially

with the greatest reductions (85%) seen in the younger children (1-5 years). More than two years after

cessation of IRS, rebound in 2017 was rapid in all age groups, except for the younger children (1-5 years)

where those up to 59 months were targeted by SMC. Population sizes in adolescents (11-20 years) and

adults (> 20 years) showed they carried more infections in 2017 than at baseline in 2012. This is indicative

of a loss of immunity during IRS which may relate to the observed loss of *var* richness, especially the many

rare types. This warrants further investigation of changes in variant-specific immunity. During and

following the IRS and SMC interventions, *var* diversity remained high and *var* repertoire overlap remained

low, reflecting characteristic properties of high transmission and demonstrating the overall resilience of

the species to survive significant short-term perturbations. Combining interventions and targeting older

age groups or the whole community with chemoprevention would no doubt have a much greater impact

on reducing the diversity of the reservoir of infection.

What was striking about the Bongo study was the speed with which rebound in MOI$_{var}$ per person and

census population size occurred, once the short-term IRS was discontinued. We looked for a potential

explanation in our genetic data. PTS and population frequency data showed that many of the DBLα types

occurred in multiple repertoires or genomes. This enabled the survival of these more frequent DBLα types

through the interventions, facilitating rebound by maintenance of this diversity. The other notable

population genetic result of our study was the failure to increase similarity (or relatedness by state) of *var*

repertoires by reducing transmission by > 90% via IRS. From a baseline of a very large population size with

very low overlap in repertoires you need outcrossing to create relatedness. However, this was less likely

to happen due to reduced transmission as a result of IRS. Rebound, with associated increases in

transmission, led to a small increase in *var* repertoire similarity. This is the opposite to what has been

observed in areas of lower transmission under intense malaria control where the intensity of interventions

led to increased genome similarity, as assessed by IBD, from a starting point of much lower genome

diversity and greater relatedness (Daniels et al., 2015).

Our molecular approach to measure population size has been to sum MOI$_{var}$ in individual hosts with

microscopically-detectable infections. Like any diagnostic method there are limits to sensitivity and

specificity, which can be more or less tolerated dependent upon the purpose of the study. Here we have

looked at relative changes in population size with sequential interventions using an interrupted time-

series study design and observed changes by measuring MOI$_{var}$. We have accounted for missing DBLα type

data where complete *var* repertoires may not have been sequenced using a Bayesian method based on

empirical knowledge of the measurement error. This approach has conceptual relation to the Bayesian

approach by Johnson and Larremore (Johnson and Larremore, 2022) to estimate complete repertoire size

of, and overlap between, monoclonal infections from incomplete sampling of DBLα types. Our

measurement of population size based on MOI_{var} will be subject to other sampling errors which may in

the end be more significant (discussed in detail in Labbé et al. (Labbé et al., 2023)). For example, low

parasitemia typical of asymptomatic infections, small blood volumes, clinical status, and/or within host

dynamics, including synchronicity, will all create sampling problems, but these are common to all

measures of MOI.

Previously, we have drawn attention to the potential underestimation of the number of DBLα types of

related parasites generated by a cross, when using *var* genotyping (Labbé et al., 2023). Such related

parasites must be created frequently in high transmission due to extensive outcrossing (Babiker et al.,

1994; Paul et al., 1995). Single clone genomics experiments using biallelic SNPs from whole genome

sequencing data have also detected related parasites using IBD in clinical infections from humans in a

high-transmission area of Malawi (Nkhoma et al., 2020). Here we have analysed low- to moderate-density,

chronic, asymptomatic infections (see Table supplement 1) under strong immune selection in semi-

immune hosts whom we have shown select against parasites with high PTS scores consistent with

relatedness by decent (Day et al., 2017; He et al., 2018; Ruybal-Pesántez et al., 2022). When considering

the importance of possible exclusion of parasites related by descent, the only sure way to detect such

parasites in high transmission is by single cell genomics, a methodology of limited application to malaria

surveillance due to practicality and cost of scale up. Again, the error from failure to sample infections

related by descent must be weighed up against the issues of under-sampling as described above.

The Bayesian approach of the *var*coding method relies on the low or limiting similarity of *var* repertoires

infecting individual human hosts. As such, it would appear to break down as the *var* repertoire overlap

moves away from extremely low, and therefore, for locations with lower transmission intensity.

Interestingly, this is not the case in the numerical simulations of Labbé et al. (Labbé et al., 2023), for a

gradient of three transmission intensities, from high to low, with the original *var*coding method

performing well across the gradient. This robustness of the method may arise from a nonlinear and fast

transition from low to high overlap that is accompanied by MOI changing rapidly from primarily

multiclonal (MOI > 1) to monoclonal (MOI = 1) infections. This matter needs to be investigated further in

the future, including ways to extend the Bayesian approach to explicitly include the distribution of *var*

repertoire overlap.

In summary, our findings provide parasite population insights into why rebound is the inevitable

consequence of such short-term IRS interventions unless you simultaneously target the highly diverse,

long-lived parasite population in humans, not just children < 5 years by SMC. Of potential translational

significance for malaria molecular surveillance, we identify new metrics, especially MOI$_{var}$ and census

population size as well as *var* frequency category, informative to monitor and evaluate interventions in

high-transmission areas with multiclonal infections and high rates of outcrossing. Such metrics could be

used longitudinally to detect incremental gains of transmission-reducing interventions, including IRS,

LLINs, and vaccines to perturb the high-transmission characteristics of the parasite population in humans

in high-burden countries in SSA.

ACKNOWLEDGMENTS. This research was supported by Fogarty International Center at the National

Institutes of Health through the joint NIH-NSF-NIFA Ecology and Evolution of Infectious Diseases award

R01-TW009670 to K.A.K, M.P, and K.P.D; and the National Institute of Allergy and Infectious Diseases,

National Institutes of Health through the joint NIH-NSF-NIFA Ecology and Evolution of Infectious Diseases

award R01-AI149779 to A.R.O, K.A.K, M.P, and K.P.D. We wish to thank the participants, communities, and

the Ghana Health Service in Bongo District, Ghana for their willingness to participate in this study. We

would like to thank the field teams in Bongo for their technical assistance in the field, as well as the

laboratory personnel at the Navrongo Health Research Centre for their expertise and for undertaking the

sample collections and parasitological assessments.

REFERENCES

Anderson TJC, Haubold B, Williams JT, Estrada-Franco JG, Richardson L, Mollinedo R, Bockarie M, Mokili J, Mharakurwa S, French N, Whitworth J, Velez ID, Brockman AH, Nosten F, Ferreira MU, Day KP, Estrada-Franco JG, Richardson L, Mollinedo R, Bockarie M, Mokili J, Mharakurwa S, French N, Whitworth J, Velez ID, Brockman AH, Nosten F, Ferreira MU, Day KP. 2000. Microsatellite markers reveal a spectrum of population structures in the malaria parasite Plasmodium falciparum. *Mol Biol Evol* **17**:1467–1482. doi:10.1093/oxfordjournals.molbev.a026247

Babiker HA, Ranford-Cartwright LC, Currie D, Charlwood JD, Billingsley P, Teuscher T, Walliker D. 1994. Random mating in a natural population of the malaria parasite Plasmodium falciparum. *Parasitology* **109**:413–421. doi:10.1017/S0031182000080665

Barry AE, Leliwa-Sytek A, Tavul L, Imrie H, Migot-Nabias F, Brown SM, McVean GA V, Day KP. 2007. Population genomics of the immune evasion (var) genes of Plasmodium falciparum. *PLoS Pathog* **3**:e34. doi:10.1371/journal.ppat.0030034

Bedford T, Cobey S, Pascual M. 2011. Strength and tempo of selection revealed in viral gene genealogies. *BMC Evol Biol* **11**. doi:10.1186/1471-2148-11-220

Bruce MC, Galinski MR, Barnwell JW, Donnelly CA, Walmsley M, Alpers MP, Walliker D, Day KP. 2000. Genetic diversity and dynamics of plasmodium falciparum and P. vivax populations in multiply infected children with asymptomatic malaria infections in Papua New Guinea. *Parasitology* **121 (** Pt **3**:257–272. doi:10.1017/S0031182099006356

Charlesworth B. 2009. Fundamental concepts in genetics: Effective population size and patterns of molecular evolution and variation. *Nat Rev Genet*. doi:10.1038/nrg2526

Chen DS, Barry AE, Leliwa-Sytek A, Smith T-AA, Peterson I, Brown SM, Migot-Nabias F, Deloron P, Kortok MM, Marsh K, Daily JP, Ndiaye D, Sarr O, Mboup S, Day KP. 2011. A molecular epidemiological study of var gene diversity to characterize the reservoir of Plasmodium falciparum in humans in Africa. *PLoS One* **6**:e16629. doi:10.1371/journal.pone.0016629

Daniels RF, Schaffner SF, Wenger E a., Proctor JL, Chang H-H, Wong W, Baro N, Ndiaye D, Fall FB, Ndiop M, Ba M, Milner D a., Taylor TE, Neafsey DE, Volkman SK, Eckhoff P a., Hartl DL, Wirth DF. 2015. Modeling malaria genomics reveals transmission decline and rebound in Senegal. *PNAS* **112**:7067–7072. doi:10.1073/pnas.1505691112

Day KP, Artzy-Randrup Y, Tiedje KE, Rougeron V, Chen DS, Rask TS, Rorick MM, Migot-Nabias F, Deloron P, Luty AJF, Pascual M. 2017. Evidence of Strain Structure in Plasmodium falciparum Var Gene Repertoires in Children from Gabon, West Africa. *PNAS* **114**:E4103–E4111. doi:10.1073/pnas.1613018114

Dietz K. 1988. Mathematical models for transmission and control of malariaMalaria: Principles and Practice of Malariology.

Falk N, Kaestli M, Qi W, Ott M, Baea K, Cortés A, Beck H-P. 2009. Analysis of Plasmodium falciparum var genes expressed in children from Papua New Guinea. *Journal of infectious diseases* **200**:347–356. doi:10.1086/600071

Falk N, Maire N, Sama W, Owusu-Agyei S, Smith T, Beck HP, Felger I. 2006. Comparison of PCR-RFLP and genescan-based genotyping for analyzing infection dynamics of Plasmodium falciparum. *American Journal of Tropical Medicine and Hygiene* **74**:944–950.

Farnert A, Snounou G, Rooth I, Bjorkman A. 1997. Daily dynamics of Plasmodium falciparum
subpopulations in asymptomatic children in a holoendemic area. *American Journal of Tropical*
Medicine and Hygiene **56**:538–547. doi:10.4269/ajtmh.1997.56.538
Futse JE, Brayton KA, Dark MJ, Knowles DP, Palmer GH. 2008. Superinfection as a driver of genomic
diversification in antigenically variant pathogens. *Proc Natl Acad Sci U S A* **105**:2123–2127.
doi:10.1073/pnas.0710333105
Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S,
Paulsen IT, James K, Eisen J a, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan M-S, Nene V, Shallom
SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin
DMA, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph S a, McFadden GI, Cummings LM, Subramanian
GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B. 2002.
Genome sequence of the human malaria parasite Plasmodium falciparum. *Nature* **419**:498–511.
doi:10.1038/nature01097
Ghansah A, Tiedje KE, Argyropoulos DC, Onwona CO, Deed SL, Labbé F, Oduro AR, Koram KA, Pascual M,
Day KP. 2023. Comparison of molecular surveillance methods to assess changes in the population
genetics of Plasmodium falciparum in high transmission. *Frontiers in Parasitology* **2**:1067966.
Gogue C, Wagman J, Tynuv K, Saibu A, Yihdego Y, Malm K, Mohamed W, Akplu W, Tagoe T, Ofosu A,
Williams I, Asiedu S, Richardson J, Fornadel C, Slutsker L, Robertson M. 2020. An observational
analysis of the impact of indoor residual spraying in Northern, Upper East, and Upper West Regions
of Ghana: 2014 through 2017. *Malar J* **19**:1–13. doi:10.1186/s12936-020-03318-1
He Q, Pilosof S, Tiedje KE, Ruybal-Pesántez S, Artzy-Randrup Y, Baskerville EB, Day KP, Pascual M. 2018.
Networks of genetic similarity reveal non-neutral processes shape strain structure in Plasmodium
falciparum. *Nat Commun* **9**:1817. doi:10.1038/s41467-018-04219-3
Henry JM. 2020. A hybrid model for the effects of treatment and demography on malaria superinfection.
J Theor Biol **491**:110194.
Jensen ATR, Magistrado P, Sharp S, Joergensen L, Lavstsen T, Chiucchiuini A, Salanti A, Vestergaard LS,
Lusingu JP, Hermsen R, Sauerwein R, Christensen J, Nielsen MA, Hviid L, Sutherland C, Staalsoe T,
Theander TG. 2004. Plasmodium falciparum associated with severe childhood malaria preferentially
expresses PfEMP1 encoded by group A var genes. *J Exp Med* **199**:1179–1190.
doi:10.1084/jem.20040274
Johnson EK, Larremore DB. 2022. Bayesian estimation of community size and overlap from random
subsamples. *PLoS Comput Biol* **18**:1–16. doi:10.1371/journal.pcbi.1010451
Kaestli M, Cockburn I a, Cortés A, Baea K, Rowe JA, Beck H-P. 2006. Virulence of malaria is associated with
differential expression of Plasmodium falciparum var gene subgroups in a case-control study. *J Infect*
Dis **193**:1567–1574. doi:JID35650 [pii]\n10.1086/503776
Kalmbach Y, Rottmann M, Kombila M, Kremsner PG, Beck H-P, Kun JFJ. 2010. Differential var gene
expression in children with malaria and antidromic effects on host gene expression. *Journal of*
Infectious Diseases **202**:313–317. doi:10.1086/653586
Kassambara A, Kosinski M, Biecek P, Scheipl F. 2021. survminer: Drawing Survival Curves using ggplot2.
Kraemer SM, Kyes SA, Aggarwal G, Springer AL, Nelson SO, Christodoulou Z, Smith LM, Wang W, Levin E,
Newbold CI, Myler PJ, Smith JD. 2007. Patterns of gene recombination shape var gene repertoires in
Plasmodium falciparum: comparisons of geographically diverse isolates. *BMC Genomics* **8**:45.
doi:10.1186/1471-2164-8-45

Kraemer SM, Smith JD. 2006. A family affair: var genes, PfEMP1 binding, and malaria disease. *Curr Opin*
Microbiol. doi:10.1016/j.mib.2006.06.006

Kyriacou HM, Stone GN, Challis RJ, Raza A, Lyke KE, Thera MA, Koné AK, Doumbo OK, Plowe C V., Rowe JA.
2006. Differential var gene transcription in Plasmodium falciparum isolates from patients with
cerebral malaria compared to hyperparasitaemia. *Mol Biochem Parasitol* **150**:211–218.
doi:10.1016/j.molbiopara.2006.08.005

Labbé F, He Q, Zhan Q, Tiedje KE, Argyropoulos DC, Tan MH, Ghansah A, Day KP, Pascual M. 2023. Neutral
vs . non-neutral genetic footprints of Plasmodium falciparum multiclonal infections. *PLoS Comput*
Biol **19**:e1010816. doi:doi.org/10.1101/2022.06.27.497801

LaVerriere E, Schwabl P, Carrasquilla M, Taylor AR, Johnson ZM, Shieh M, Panchal R, Straub TJ, Kuzma R,
Watson S, Buckee CO, Andrade CM, Portugal S, Crompton PD, Traore B, Rayner JC, Corredor V, James
K, Cox H, Early AM, MacInnis BL, Neafsey DE. 2022. Design and implementation of multiplexed
amplicon sequencing panels to serve genomic epidemiology of infectious disease: A malaria case
study. *Mol Ecol Resour* 2285–2303. doi:10.1111/1755-0998.13622

Lavstsen T, Salanti A, Jensen ATR, Arnot DE, Theander TG. 2003. Sub-grouping of Plasmodium falciparum
3D7 var genes based on sequence analysis of coding and non-coding regions. *Malar J* **2**:27.
doi:10.1186/1475-2875-2-27

Lerch A, Koepfli C, Hofmann NE, Kattenberg JH, Rosanas-Urgell A, Betuela I, Mueller I, Felger I. 2019.
Longitudinal tracking and quantification of individual Plasmodium falciparum clones in complex
infections. *Sci Rep* **9**:1–8. doi:10.1038/s41598-019-39656-7

Lerch A, Koepfli C, Hofmann NE, Messerli C, Wilcox S, Kattenberg JH, Betuela I, O'Connor L, Mueller I,
Felger I. 2017. Development of amplicon deep sequencing markers and data analysis pipeline for
genotyping multi-clonal malaria infections. *BMC Genomics* **18**:1–13. doi:10.1186/s12864-017-4260-
y

Markwalter CF, Menya D, Wesolowski A, Esimit D, Lokoel G, Kipkoech J, Freedman E, Sumner KM, Abel L,
Ambani G, Meredith HR, Taylor SM, Obala AA, O'Meara WP. 2022. Plasmodium falciparum
importation does not sustain malaria transmission in a semi-arid region of Kenya. *PLOS Global Public*
Health **2**:e0000807. doi:10.1371/journal.pgph.0000807

Nelson CS, Sumner KM, Freedman E, Saelens JW, Obala AA, Mangeni JN, Taylor SM, O'Meara WP. 2019.
High-resolution micro-epidemiology of parasite spatial and temporal dynamics in a high malaria
transmission setting in Kenya. *Nat Commun* **10**. doi:10.1038/s41467-019-13578-4

Nkhoma SC, Trevino SG, Gorena KM, Nair S, Khoswe S, Jett C, Garcia R, Daniel B, Dia A, Terlouw DJ, Ward
SA, Anderson TJC, Cheeseman IH. 2020. Co-transmission of Related Malaria Parasite Lineages Shapes
Within-Host Parasite Diversity. *Cell Host Microbe* **27**:93-103.e4. doi:10.1016/j.chom.2019.12.001

Normark J, Nilsson D, Ribacke U, Winter G, Moll K, Wheelock CE, Bayarugaba J, Kironde F, Egwang TG,
Chen Q, Andersson B, Wahlgren M. 2007. PfEMP1-DBL1alpha amino acid motifs in severe disease
states of Plasmodium falciparum malaria. *Proc Natl Acad Sci U S A* **104**:15835–40.
doi:10.1073/pnas.0610485104

Otto TD, Assefa SA, Böhme U, Sanders MJ, Kwiatkowski DP, Berriman M, Newbold C. 2019. Evolutionary
analysis of the most polymorphic gene family in falciparum malaria. *Wellcome Open Res* **4**:1–29.
doi:10.12688/wellcomeopenres.15590.1

Palstra FP, Fraser DJ. 2012. Effective/census population size ratio estimation: A compendium and
appraisal. *Ecol Evol* **2**:2357–2365. doi:10.1002/ece3.329

Paul RE, Packer MJ, Walmsley M, Lagog M, Ranford-Cartwright LC, Paru R, Day KP. 1995. Mating patterns
in malaria parasite populations of Papua New Guinea. *Science (1979)* **269**:1709–1711.

R Core Team. 2018. R: A Language and Environment for Statistical Computing. *R Foundation for Statistical*
Computing.

Rask TS, Hansen D, Theander TG, Pedersen AG, Lavstsen T, Gorm Pedersen A, Lavstsen T, Pedersen AG,
Lavstsen T, Gorm Pedersen A, Lavstsen T. 2010. Plasmodium falciparum erythrocyte membrane
protein 1 diversity in seven genomes - divide and conquer. *PLoS Comput Biol* **6**:e1000933.
doi:10.1371/journal.pcbi.1000933

Rottmann M, Lavstsen T, Mugasa JP, Kaestli M, Jensen ATR, Müller D, Theander T, Beck H-PP. 2006.
Differential expression of var gene groups is associated with morbidity caused by Plasmodium
falciparum infection in Tanzanian children. *Infect Immun* **74**:3904–3911. doi:10.1128/IAI.02073-05

Ruybal-Pesántez S, Tiedje KE, Pilosof S, Tonkin-Hill G, He Q, Rask TS, Amenga-Etego L, Oduro AR, Koram
KA, Pascual M, Day KP. 2022. Age-specific patterns of DBLa var diversity can explain why residents of
high malaria transmission areas remain susceptible to Plasmodium falciparum blood stage infection
throughout life. *Int J Parasitol* **20**:721–731.

Ruybal-Pesántez S, Tiedje KE, Tonkin-Hill G, Rask TS, Kamya MR, Greenhouse B, Dorsey G, Duffy MF, Day
KP. 2017. Population genomics of virulence genes of Plasmodium falciparum in clinical isolates from
Uganda. *Sci Rep* **7**:11810. doi:10.1038/s41598-017-11814-9

Sjoberg, D, Whiting K, Curry M, Lavery J, Larmarange J. 2021. Reproducible Summary Tables with the
gtsummary Package. *R J* **13**:570–580.

Smith T, Felger I, Fraser-Hurt N, Beck H-PP. 1999. Effect of insecticide-treated falciparum infections bed
nets on the dynamics of multiple Plasmodium falciparum infections. *Trans R Soc Trop Med Hyg* **93**
(Supp):S1/53-S1/57. doi:10.1016/S0035-9203(99)90328-0

Speed D, Balding DJ. 2015. Relatedness in the post-genomic era: Is it still useful? *Nat Rev Genet* **16**:33–44.
doi:10.1038/nrg3821

Stevenson M. 2020. epiR: Tools for the analysis of epidemiological data.

Sumner KM, Freedman E, Abel L, Obala A, Pence BW, Wesolowski A, Meshnick SR, Prudhomme-O'Meara
W, Taylor SM. 2021. Genotyping cognate Plasmodium falciparum in humans and mosquitoes to
estimate onward transmission of asymptomatic infections. *Nat Commun* **12**:1–12.
doi:10.1038/s41467-021-21269-2

Tan MH, Shim H, Chan Y, Day KP. 2023. Unravelling chaos for malaria surveillance : Relationship between
DBLα types and var genes in Plasmodium falciparum. *Frontiers in Parasitology* **1**.
doi:https://doi.org/10.3389/fpara.2022.1006341

Tessema SK, Hathaway NJ, Teyssier NB, Murphy M, Chen A, Aydemir O, Duarte EM, Simone W, Colborn J,
Saute F, Crawford E, Aide P, Bailey JA, Greenhouse B. 2020. Sensitive, highly multiplexed sequencing
of microhaplotypes from the Plasmodium falciparum heterozygome. *Journal of Infectious Diseases*
225:1227–1237.

Therneau T. 2023. A Package for Survival Analysis in R.

Tiedje KE, Oduro AR, Agongo G, Anyorigiya T, Azongo D, Awine T, Ghansah A, Pascual M, Koram KA, Day
KP. 2017. Seasonal Variation in the Epidemiology of Asymptomatic Plasmodium falciparum Infections
Across Two Catchment Areas in Bongo District, Ghana. *Am J Trop Med Hyg* **97**:199–212.
doi:10.4269/ajtmh.16-0959

Tiedje KE, Oduro AR, Bangre O, Amenga-Etego L, Dadzie SK, Appawu MA, Frempong K, Asoala V, Charles
A Narh, Samantha L Deed, Ruybal-Pesántez S, Argyropoulos DC, Anita Ghansah, Agyei SA, Segbaya S,

Desewu K, Williams I, Simpson JA, Malm K, Pascual M, Koram KA, Day KP. 2022. Indoor residual
spraying with a non-pyrethroid insecticide reduces the reservoir of Plasmodium falciparum in a high-
transmission area in northern Ghana. *PLOS Global Public Health* **2**:e0000285.
doi:10.1371/journal.pgph.0000285

US Agency for International Development (USAID) Global Health Supply Chain Program. 2020. Technical
Breif: Data visability makes all the difference in Ghana's 2018 LLIN mass distribution campaign.

US President's Malaria Initiative Africa IRS (AIRS) Project. 2016. Entomological monitoring of the PMI AIRS
program in northern Ghana: 2016 annual report. Bethesda, Marland, USA.

Wagman J, Gogue C, Tynuv K, Mihigo J, Bankineza E, Bah M, Diallo D, Saibu A, Richardson JH, Kone D,
Fomba S, Bernson J, Steketee R, Slutsker L, Robertson M. 2018. An observational analysis of the
impact of indoor residual spraying with non-pyrethroid insecticides on the incidence of malaria in
Ségou Region, Mali: 2012–2015. *Malar J* **17**:19. doi:10.1186/s12936-017-2168-2

Warimwe GM, Fegan G, Musyoki JN, Newton CRJC, Opiyo M, Githinji G, Andisi C, Menza F, Kitsao B, Marsh
K, Bull PC. 2012. Prognostic indicators of life-threatening malaria are associated with distinct parasite
variant antigen profiles. *Sci Transl Med* **4**:129ra45. doi:10.1126/scitranslmed.3003247

Warimwe GM, Keane TM, Fegan G, Musyoki JN, Newton CRJC, Pain A, Berriman M, Marsh K, Bull PC. 2009.
Plasmodium falciparum var gene expression is modified by host immunity. *Proc Natl Acad Sci U S A*
106:21801–21806.

Watson OJ, Okell LC, Hellewell J, Slater HC, Unwin HJT, Omedo I, Bejon P, Snow RW, Noor AM, Rockett K,
Hubbart C, Nankabirwa JI, Greenhouse B, Chang HH, Ghani AC, Verity R. 2021. Evaluating the
Performance of Malaria Genetics for Inferring Changes in Transmission Intensity Using Transmission
Modeling. *Mol Biol Evol* **38**:274–289. doi:10.1093/molbev/msaa225

WHO. 2012. WHO Policy Recommendation: Seasonal Malaria Chemoprevention (SMC) for Plasmodium
falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa.

WHO/GMP. 2017. A Framework for Malaria Elimination, Geneva World Health Organization.

Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, Grolemund G, Hayes A, Henry L, Hester
J, Kuhn M, Pedersen T, Miller E, Bache S, Müller K, Ooms J, Robinson D, Seidel D, Spinu V, Takahashi
K, Vaughan D, Wilke C, Woo K, Yutani H. 2019. Welcome to the Tidyverse. *J Open Source Softw*
4:1686. doi:10.21105/joss.01686

World Health Organization. 2022. World Malaria Report 2022, World Health Organization. doi:ISBN 978
92 4 1564403

Zhang X, Deitsch KW. 2022. The mystery of persistent, asymptomatic Plasmodium falciparum infections.
Curr Opin Microbiol **70**:102231. doi:10.1016/j.mib.2022.102231

805
806

DATA AVAILABILITY STATEMENT. The sequences utilized in this study are publicly available in GenBank

under BioProject Number: PRJNA 396962. All data associated with this study are available in the main text,

the Supporting Information, or upon reasonable request by contacting the Malaria Reservoir Study Team,

represented by the corresponding author, Prof. Karen Day (karen.day@unimelb.edu.au), to discuss how

these data will be utilized for academic or research purposes and, if appropriate, to explore opportunities

for collaboration. All custom code is available in an open source repository: (1) DBLαCleaner pipeline is

available athttps://github.com/UniMelb-Day-Lab/DBLaCleaner, (2) clusterDBLalpha pipeline is available at

https://github.com/Unimelb-Day-Lab/clusterDBLalpha, and the (3) classifyDBLalpha pipeline is available

at https://github.com/Unimelb-Day-Lab/classifyDBLalpha. A dataset to demo this custom code is available

at https://github.com/UniMelb-Day-Lab/tutorialDBLalpha. For additional information on the use of the

Bayesian approach to estimate MOI_{var} please see https://github.com/qzhan321/Bayesian-formulation-

varcoding-MOI-estimation.

BENEFIT-SHARING STATEMENT. A research collaboration was developed with scientists from Ghana

based at the Navrongo Health Research Centre and the Noguchi Memorial Institute for Medical Research.

All collaborators are included as co-authors and the relevant results from the research has been shared

with key stakeholders and the local community (i.e., Paramount Chief of Bongo District, divisional Chiefs,

Queen Mothers, and community members), the Bongo District and Upper East Regional Health

Directorates, as well as Ghana National Malaria Elimination Programme. Before this research was

undertaken, informed consent was sought and obtained from the key stakeholders, traditional leadership,

and the local community in Bongo District. In addition, members of the local community were trained as

field workers and were directly involved in liaising with the community and in the collection of the study

data. The contribution of these individuals to this research is described in the Acknowledgements. This

research addresses a priority concern regarding malaria control and the impact of interventions. These

concerns are relevant for both the local community in Bongo District, as well as for the National Malaria

Elimination Programme in Ghana.

AUTHOR CONTRIBUTIONS.   K.P.D and M.P conceptualized the study of population size using MOI_{var}. K.A.K

and K.P.D conceived and designed the field study with input from A.R.O and K.E.T, who together with O.B

coordinated the field studies. K.E.T, S.R-P, and S.L.D processed the samples and performed the genotyping

experiments. G.T-H developed and validated the bioinformatic pipelines. K.E.T, S.R-P, and D.C.A

processed, cleaned, and curated the datasets for analysis. Q.Z developed and implemented the Bayesian

estimations. K.E.T, Q.Z, M.P, and K.P.D analysed the data with contributions from S.R-P, Q.H, and M-H.T.

K.E.T and Q.Z visualized the data. K.P.D, M.P, and K.E.T wrote the original draft of the manuscript. Q.Z.,

S.R-P, G.T-H, Q.H, M-H.T, D.C.A, S.L.D, O. B, A.R.O, and K.AK reviewed and edited manuscript. M.P and K.P.D

supervised the research. A.R.O, K.A.K, M.P, and K.P.D acquired the funding.

COMPETING INTERESTS. The authors declare no competing interests.

Figure 1. Study design and changes in the prevalence of microscopic *P. falciparum* infection following the IRS and SMC interventions in Bongo, Ghana. (A) Four age-stratified cross-sectional surveys of ~2,000 participants per survey were conducted in Bongo, Ghana at the end of the wet seasons in October 2012 (Survey 1, baseline pre-IRS, red), October 2014 (Survey 2, during IRS, orange), October 2015 (Survey 3, post-IRS, green), and October 2017 (Survey 4, SMC, purple) (Table supplement 1) (see Materials and Methods). The three rounds of IRS (grey areas) were implemented between 2013 and 2015 (Tiedje et al., 2022). SMC was distributed to all children < 5 years of age during the wet seasons in 2016 (two rounds between August – September 2016) and 2017 (four rounds between September – December 2017) (Gogue et al., 2020). Both IRS and SMC were implemented against a background of widespread LLIN usage (Tiedje et al., 2022). Prevalence of microscopic *P. falciparum* infections (%) in the (B) study population and (C) for all age groups (years) in each survey. Error bars represent the upper and lower limits of the 95% confidence interval (CI) calculated using the Wald Interval.

859
Figure 2. Sharing of upsA and non-upsA DBLα types among the DBLα isolate repertoires in 2012 (pre-
IRS, red), 2014 (during IRS, orange), 2015 (post-IRS, green), and 2017 (SMC, purple). The overlapping
density and violin plots (upper right-hand corners) show the distribution of PTS scores (i.e., DBLα isolate
repertoire similarity) between the (A) upsA and (B) non-upsA DBLα isolate repertoires for those isolates
with DBLα sequencing data (Table supplement 2) in each survey. The PTS scales in the density plots have
been zoomed-in to provide better visualization of the upsA and non-upsA DBLα types PTS distributions.
The coloured dashed lines in the density plots indicate the median PTS scores in each survey for the upsA
(2012 (red) = 0.078, 2014 (orange) = 0.063, 2015 (green) = 0.054, and 2017 (purple) = 0.064) and non-
upsA (2012 (red) = 0.020, 2014 (orange) = 0.013, 2015 (green) = 0.013, and 2017 (purple) = 0.016) DBLα
types. *Note:* The non-upsA median PTS values in 2014 (orange) and 2015 (green) were both 0.013 and
overlap in the figure. In the PTS violin plots the central box plots indicate the medians (centre line),
interquartile ranges (IQR, upper and lower quartiles), whiskers (1.5x IQR), and outliers (points).

Figure 3. MOI*var* distributions in 2012 (pre-IRS, red), 2014 (during IRS, orange), 2015 (post-IRS, green), and 2017 (SMC, purple) based on pooling the maximum *a posteriori* MOI estimates. Estimated MOI*var* distributions for the (**A**) study population and (**B**) for all age groups (years) in each survey for those isolates with DBLα sequencing data (Table supplements 2 and 7). The median MOI*var* values are indicated with the black dashed lines and have been provided in the top right corner (median MOI*var* value [interquartile range, upper and lower quartiles]) along with the percentage of *P. falciparum* infections that were multiclonal (MOI*var* > 1) in each survey and age group (years).

Figure 4. Estimated number and relative change in the number of *P. falciparum var* repertoires in
2012 (pre-IRS, red), 2014 (during IRS, orange), 2015 (post-IRS, green), and 2017 (SMC, purple). The
estimated number of *var* repertoires (i.e., census population size) for those isolates with DBLα sequencing
data (Table supplements 2 and 7) in the (**A**) study population and (**B**) for all age groups (years). The
estimated number of *var* repertoires vs. *P. falciparum* prevalence for (**C**) study population and (**D**) for all
age groups (years) (Table supplement 7). The percentage change in *P. falciparum* prevalence (black dotted
line) and the estimated number of *var* repertoires (black solid line) in 2014, 2015, and 2017 compared to
the 2012 baseline survey (red dashed horizontal line at 0% change) for the (**E**) study population and (**F**)

for all age groups (years). Error bars in (**A-D**) represent the upper and lower limits of the 95% confidence
intervals (95% CIs). To account for differences in sampling depth across age groups and surveys, we
performed subsampling with replacement by selecting the minimum number of individuals in each age
group across all surveys. We then calculated the total number of *var* repertoires from these subsampled
individuals within each age group in each survey. This approach ensures consistent sample sizes within
each age group across all surveys. Finally, we summed the *var* repertoires across age groups to obtain the
total *var* repertoire count for each survey. The mean (coloured solid points) and 95% CIs for the number
of *var* repertoires were estimated by repeating the subsampling procedure 10,000 times. The CIs were
then derived from the distribution of these repeated subsampling replicates. The 95% CIs for *P. falciparum*
prevalence (%) were calculated using the Wald Interval.

899
Figure 5. UpsA and non-upsA DBLα type richness in 2012 (pre-IRS, red), 2014 (during IRS, orange),
2015 (post-IRS, green), and 2017 (SMC, purple). Number of unique (**A**) upsA and (**B**) non-upsA DBLα
types (i.e., richness) observed in each survey vs. *P. falciparum* prevalence based on those isolates with
DBLα sequencing data (Table supplement 2). Error bars represent the upper and lower limits of the 95%
confidence intervals (95% CIs) for the *P. falciparum* prevalence (%; x-axis) and ± 2 standard deviations (±
2SD) for the number of unique upsA and non-upsA DBLα types (y-axis). The 95% CIs for *P. falciparum*
prevalence (%) were calculated using the Wald Interval. The ± 2SD for the number of unique upsA and
non-upsA DBLα types were calculated based on a bootstrap approach. We resampled 10,000 replicates
from the original population-level distribution with replacement. Each resampled replicate has the same
size as the original sample. We then derive the standard deviation (SD) based on the distribution of the
resampled replicates.

Figure 6. UpsA and non-upsA DBLα type frequencies and survival in 2012 (pre-IRS, red), 2014 (during IRS, orange), 2015 (post-IRS,
green), and 2017 (SMC, purple). Heatmaps showing the patterns of diversity for the (**A**) upsA and (**B**) non-upsA DBLα types. The
columns represent all the upsA and non-upsA DBLα types observed in the four surveys, and the rows represent each of the 2,802 upsA
DBLα types and the 50,436 non-upsA DBLα types (Table supplement 2). White rows are used to denote the absence of a specific DBLα
type, while the presence of a DBLα type is indicated in colour and further categorised (colour gradations) based on the frequency or the
number of times (i.e., number of isolates) a DBLα type was observed in each survey (Frequency categories: 1, 2-10, 11-20, > 20 isolates;

Note the frequency category cut-offs were chosen based on the frequency distributions in Figure supplement 7). The proportions of (**C**)
upsA and (**D**) non-upsA DBLα types in each survey based on the number of times (i.e., number of isolates) they were observed in each
survey. Kaplan-Meier survival curves for the (**E**) upsA and (**F**) non-upsA DBLα types across time (2012 to 2017) categorised based on
their frequency at baseline in 2012 (pre-IRS, red). The coloured shaded areas represent the upper and lower limits of the 95% confidence
intervals (95% CIs) with the number (N) of upsA and non-upsA DBLα types in each frequency category are provided in parenthesis. These
survival curves include only those upsA (N = 2,218) and non-upsA (N = 33,159) DBLα types that were seen at baseline in 2012 (pre-IRS)
as indicated in red (Table supplement 2). The x-axis indicates time where time "0" denotes 2012 (pre-IRS), "1" denotes 2014 (during
IRS), "2" denotes 2015 (post-IRS), and finally "3" denotes 2017 (SMC). *Note:* In the survival curves the 11-20 and > 20 frequency
categories for both the (**E**) upsA and (**F**) non-upsA DBLα types overlap in the figure.